文献速递呼吸道感染

成人社区获得性与医院获得性肺炎试验核心结局集:ERS声明

Core outcome set for trials evaluating the management of community-acquired and nosocomial pneumonia in adults: an ERS statement.
PubMed 文献 · Eur Respir J · 2026-07-23

欧洲呼吸学会工作组通过系统综述、患者访谈及涉及58国289名参与者的两轮德尔菲调查,制定了两套肺炎临床试验核心结局集。社区获得性肺炎核心结局集含治疗成功/失败、全因死亡、严重不良事件等,医院获得性肺炎核心结局集含治疗成功/失败、全因死亡、严重不良事件、再入院和通气支持需求,旨在提升证据一致性与可比性。

要点

  • 社区获得性肺炎试验核心结局包括治疗成功/失败、全因死亡、严重不良事件等六项。
  • 医院获得性肺炎试验核心结局包括治疗成功/失败、全因死亡、严重不良事件等五项。
  • 专家组建议全因死亡在入组后30天测量,再入院在出院后30天测量。

核心结论

  • 两套核心结局集为成人社区获得性和医院获得性肺炎临床试验提供了标准化结局选择框架。

研究设计与样本

  • 多阶段多利益相关方流程,包括系统综述、患者定性访谈和两轮在线德尔菲调查,共289名来自58个国家的参与者。
  • 最终结局通过2025年4月两次虚拟共识会议的结构化投票确定。

主要发现

  • 社区获得性肺炎核心结局集包含治疗成功/失败、全因死亡、严重不良事件、再入院(社区试验为入院)、症状持续时间和临床稳定时间(住院患者)。
  • 医院获得性肺炎核心结局集包含治疗成功/失败、全因死亡、严重不良事件、再入院和通气支持需求。

关键数值与推荐

  • 专家组建议全因死亡在入组后30天测量,再入院在出院后30天测量。

临床怎么用

  • 未来肺炎临床试验应参考该核心结局集选择结局指标,以提高研究的相关性、质量和可比性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical trials assessing the management of pneumonia use heterogeneous outcomes, often lacking patient relevance or standardisation. We developed two core outcome sets (COSs) for future clinical trials evaluating interventions in community-acquired pneumonia (CAP) and nosocomial pneumonia (hospital-acquired pneumonia and ventilator-associated pneumonia) to improve the consistency and comparability of evidence. METHODS: A multistage, multistakeholder process was undertaken, comprising 1) a systematic review of previously used outcomes conducted by our team, 2) qualitative interviews with patients and 3) a two-round online Delphi survey involving 289 participants (patients, relatives and healthcare professionals) from 58 countries. This diverse sample ensured a broad representation of clinical and patient perspectives. Final outcomes were agreed upon through structured voting in two virtual consensus meetings in April 2025. RESULTS: The final COS for CAP includes: treatment success/failure, all-cause mortality, serious adverse events, readmissions (admission for community-based trials), duration of symptoms and time to clinical stability (for hospitalised patients). The nosocomial pneumonia COS includes: treatment success/failure, all-cause mortality, serious adverse events, readmission and need for ventilatory support. The panel suggested measuring mortality at 30 days from study enrolment and readmission at 30 days post-discharge. CONCLUSIONS: These COSs, developed by a European Respiratory Society Task Force, provide a standardised framework for outcome selection in pneumonia trials and were informed by broad stakeholder input, including patients. Their use is expected to improve the relevance, quality and comparability of future research in pneumonia.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Fally, Cilloniz, Linnell, et al. Core outcome set for trials evaluating the management of community-acquired and nosocomial pneumonia in adults: an ERS statement. Eur Respir J. 2026. PMID: 42276741. doi:10.1183/13993003.01926-2025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。